Skip to Main Content

WASHINGTON — Seeking new ways to lower drug prices, White House advisers have raised the prospect of fast-tracking the review process for some brand-name medications submitted for approval to the Food and Drug Administration.

The FDA already prioritizes the review of drugs that are the first, second, and third generics of any given brand. The new idea, outlined in a report from the Council of Economic Advisers released Friday, might expand such a policy to brand-name drugs that treat similar diseases but can’t be interchanged like generics can be.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED